Statistics
For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section. n/a Confirmed The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Give P values as exact values whenever suitable.
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated Our web collection on statistics for biologists contains articles on many of the points above.
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Data analysis
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub The source data underlying Fig. 3a, 3c , 3g, 3i, 3i, 4a, 4b and 5, and Supplementary Fig. 1a , 1c, 1g, 2, 3,4 and 6 are provided as a Source Data file. All other data that support the findings of this study are available within the article and its supplementary information files and from the corresponding author upon reasonable request.
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Antibodies
Antibodies used A total of 551 gynecological cancer patients who had undergone a preoperative 18F-FDG-PET/CT scan before initial staging surgery at Osaka University Hospital were included in the current study. Because the samples were chronologically divided into two cohorts (the primary cohort (n=426); treated between April 2007 and December 2014, the validation cohort (n=125); treated from January 2015 to October 2018), the sample size for each cohort has not been determined.
In human clinical data analyses, patients with coexisting hematologic malignancies, administration of corticosteroids or recombinant G-CSF, or acute or chronic infection were excluded, as these factors can be a cause of leukocytosis or a false-positive detection of lymph node metastasis by 18F-FDG-PET/CT.
All findings were reproducible, as more than 1 biological replicate was generally carried out, or the sample sizes were large enough to ensure the representation of the population behavior.
Samples were not randomly allocated into experimental groups. Co-variates were controlled by performing isogenic comparisons.
In vitro and in vivo studies, blinding was not relevant as samples were not randomly allocated to subgroup for analysis. In human clinical data analyses, the identity of the patients was blinded by anonymisation of the samples. Animals and other organisms Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research Laboratory animals
Wild animals
Field-collected samples
Ethics oversight
Note that full information on the approval of the study protocol must also be provided in the manuscript.
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Confirm that:
The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
A numerical value for number of cells or percentage (with statistics) is provided.
Anti-human G-CSF antibody (Santa Cruz Biotechnology), Anti-human CD33 antibody (Leica Biosystems Inc), anti-mouse CD11b antibody (Tonbo Biosciences), anti-mouse CD3e antibody (Tonbo Biosciences), and anti-mouse Gr-1 antibody (BioXCell) have been previously validated by our work (Mabuchi S, JNCI 2014 , Kawano M, Sci Rep 2015 . Anti-human S100A8 antibody (Abcam), anti-rat S100A8 antibody (BOSTER BIOLOGY), anti-rat/human S100A9 antibody (NOVUS Biologicals), anti-rat CD11b/c antibody (Miltenyi Biotec), anti-rat HIS48 antibody(Invitrogen), and anti-mouse Gr1 antibody (Biolegend) was validated as indicated on the manufacturer's website.
ME180 human cervical cancer cell line and Ishikawa human endometrial cancer cell line were perchased from the American Type Culture Collection.
Cells were authenticated by short tandem repeat method.
Cells were routinely screened as negative for mycoplasma species (EZ-PCR Mycoplasma Test Kit; Biological Industries; #20-700-20).
No commonly misidentified cell lines were used.
BALB/c nude mice, female, 5-to 6-week-old; F344/NJcl-rnu/rnu rats, female, 7-to 8-week-old. Animals were maintained under specific-pathogen-free condition and reared at a temperature of 23 ± 1.5°C and a humidity of 45 ± 15%.
The study did not involve wild animals.
The study did not involve samples collected from the field.
All procedures involving mice and rats, and their care were approved by the Institutional Animal Care and Use Committee of the Osaka University in accordance with the relevant institutional and NIH guidelines.
A total of 551 Japanese women with gynecological cancer who underwent pretreatment 18F-FDG-PET/CT scans were included (Detailed clinicopathological characteristics were described in Table 1 and Supplementary Table 2 .
Patients with newly diagnosed gynecological cancers who had undergone a preoperative 18F-FDG-PET/CT scan before initial staging surgery at Osaka University Hospital (primary cohort, from April 2007 to December 2014; validation cohort, from January 2015 to October 2018) are included in the current study. We cannot exclude potential sources of bias: self-selection bias might have been introduced by the physicians when they perform 18F-FDG-PET/CT scan. As patients who had not undergone 18F-FDG-PET/CT scan were not included in this study, this might have led to over-or under-estimation of the results.
Permission to proceed with data acquisition and analysis was obtained from the institutional review board of Osaka University Hospital.
